By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS


Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co., Inc.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





Company News
Bristol-Myers Squibb Company (BMY) Release: Secondary Analysis Of AMPLIFY-EXT Examining Predictors Of Hospitalization Presented At ESC Congress: Eliquis (Apixaban) Significantly Reduced The Risk Of All-Cause Hospitalization Versus Placebo In Patients With Venous Thromboembolism (VTE) 9/2/2014 1:24:03 PM
Bristol-Myers Squibb Company (BMY) To Take Part In Morgan Stanley (MST) Global Health Care Conference 9/2/2014 10:56:14 AM
Bristol-Myers Squibb Company (BMY) Gives Back Rights To Alder Biopharmaceuticals Inc.'s Promising Arthritis Drug Clazakizumab 9/2/2014 8:12:26 AM
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) To Present New Data On Eliquis® (Apixaban) At The European Society of Cardiology Congress 2014 8/20/2014 8:41:27 AM
Bristol-Myers Squibb Company (BMY) And Celgene (CELG) Enter Clinical Collaboration Agreement To Evaluate Immunotherapy And Chemotherapy Combination Regimen 8/20/2014 8:25:44 AM
Amgen (AMGN), Bristol-Myers Squibb Company (BMY) On The Prowl For Space In Crowded Cambridge, Massachusetts 8/19/2014 10:02:02 AM
Bristol-Myers Squibb Company (BMY) Release: European Commission Approves Eliquis (Apixaban) For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And Prevention Of Recurrent DVT And PE 7/29/2014 9:38:32 AM
Bristol-Myers Squibb Company (BMY) And Ono Pharmaceutical Company, Ltd. Announce Strategic Immuno-Oncology Collaboration In Japan, South Korea And Taiwan 7/24/2014 11:34:28 AM
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis® (Apixaban) In Patients With NVAF Undergoing Cardioversion 7/17/2014 9:42:56 AM
Bristol-Myers Squibb Company (BMY) Announces Plans For Third Quarter Submission Of A Biologics License Application For Opdivo® (Nivolumab), An Investigational PD-1 Immune Checkpoint Inhibitor, For Previously Treated Advanced Melanoma 7/10/2014 10:03:51 AM
12345678910...
//-->